The role of stereotactic ablative body radiotherapy in renal cell carcinoma: focus on oligometastatic and oligoprogressive disease.

[1]  S. Byron,et al.  Genomic and Transcriptomic Predictors of Response from Stereotactic Body Radiation Therapy in Patients with Oligoprogressive Renal Cell Carcinoma. , 2023, European Urology Oncology.

[2]  R. Campi,et al.  Is Adjuvant Immunotherapy Worth for All Patients with Clear-cell Renal Cell Carcinoma at High Risk of Recurrence? , 2022, European urology open science.

[3]  R. Uzzo,et al.  LBA66 IMmotion010: Efficacy and safety from the phase III study of atezolizumab (atezo) vs placebo (pbo) as adjuvant therapy in patients with renal cell carcinoma (RCC) at increased risk of recurrence after resection , 2022, Annals of Oncology.

[4]  S. Signoretti,et al.  LBA67 Phase III randomized study comparing perioperative nivolumab (nivo) versus observation in patients (Pts) with renal cell carcinoma (RCC) undergoing nephrectomy (PROSPER, ECOG-ACRIN EA8143), a National Clinical Trials Network trial , 2022, Annals of Oncology.

[5]  R. Hannan,et al.  The Role of Stereotactic Ablative Body Radiotherapy in Renal Cell Carcinoma. , 2022, European urology.

[6]  L. Livi,et al.  Impact of stereotactic body radiotherapy vs palliative radiotherapy on oncologic outcomes of patients with metastatic kidney cancer concomitantly treated with immune checkpoint inhibitors: a preliminary, multicentre experience , 2022, Clinical and Translational Oncology.

[7]  A. Louie,et al.  Substituting SABR for systemic therapy in oligometastatic renal cell carcinoma — buying time or time to change? , 2022, Nature Reviews Urology.

[8]  S. Loi,et al.  Stereotactic Radiotherapy and Short-course Pembrolizumab for Oligometastatic Renal Cell Carcinoma-The RAPPORT Trial. , 2021, European urology.

[9]  F. Lohr,et al.  Nivolumab in Combination with Stereotactic Body Radiotherapy in Pretreated Patients with Metastatic Renal Cell Carcinoma. Results of the Phase II NIVES Study. , 2021, European urology.

[10]  M. Burotto,et al.  711P Nivolumab + ipilimumab (N+I) vs sunitinib (S) for first-line treatment of advanced renal cell carcinoma (aRCC) in CheckMate 214: 4-year follow-up and subgroup analysis of patients (pts) without nephrectomy , 2020 .

[11]  U. Capitanio,et al.  Rates and Predictors of Perioperative Complications in Cytoreductive Nephrectomy: Analysis of the Registry for Metastatic Renal Cell Carcinoma. , 2020, European urology oncology.

[12]  W. Woodward,et al.  Defining oligometastatic disease from a radiation oncology perspective: An ESTRO-ASTRO consensus document. , 2020, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[13]  G. Calais,et al.  Stereotactic radiation therapy in the strategy of treatment of metastatic renal cell carcinoma: A study of the Getug group. , 2018, European journal of cancer.

[14]  G. Mayhew,et al.  Tracking Cancer Evolution Reveals Constrained Routes to Metastases: TRACERx Renal , 2018, Cell.

[15]  M. Nykter,et al.  The Evolutionary History of Lethal Metastatic Prostate Cancer , 2015, Nature.

[16]  C. Porta,et al.  Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†. , 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

[17]  P. Deschavanne,et al.  A review of human cell radiosensitivity in vitro. , 1996, International journal of radiation oncology, biology, physics.

[18]  P. Iversen,et al.  A randomized trial of postoperative radiotherapy versus observation in stage II and III renal adenocarcinoma. A study by the Copenhagen Renal Cancer Study Group. , 1987, Scandinavian journal of urology and nephrology.